Analgesic efficacy of Tenoxicam,Nalbuphine and Magnesium sulphate as adjuvant to intraarticular Levobupivacaine in knee art

A comparative study of the analgesic efficacy of Tenoxicam,Nalbuphine and Magnesium sulphate as adjuvant to intraarticular Levobupivacaine in knee arthroscopy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201704002155170

Enrollment

Registered

2017-03-30

Start date

2017-04-15

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Diseases Surgery knee arthroscopy

Interventions

GLT (n=30):will receive 20 ml levobupivacaine 0.5% and tenoxicam 20mg

GLN(n=30) will receive 20 ml levobupivacaine 0.5% and nalbuphine 0.1 mg/kg

GLM(n=30) will receive 20 ml levobupivacaine 0.5% and 500 mg magnesium sulphate

GLT :will receive 20 ml levobupivacaine 0.5% and tenoxicam 20mg

GLN will receive 20 ml levobupivacaine 0.5% and nalbuphine 0.1 mg/kg

GLM will receive 20 ml levobupivacaine 0.5% and 500 mg magnesium sulphate

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: -Male patients -Age 18-50 years

Exclusion criteria

Exclusion criteria: Patients will be excluded from the study if they had sickle cell disease, peripheral vascular disease, history of DVT, poorly controlled hypertension, history of allergy to the studied drug, treatment for chronic pain alcohol and substance addiction chronic use of NSAID, opiates

Design outcomes

Primary

Measure	Time frame
The primary outcome will be NRS at passive motion at 4 hours postoperative.	—

Secondary

Measure	Time frame
-Postoperative time to first request of analgesics (minutes)	—

Countries

Egypt

Contacts

Public Contactdoaa rashwan

doaa_rashwan@hotmail.com00201011270763

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026